Search Results - "Tsujikawa, Laura M"

Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulators by Tsujikawa, Laura M., Kharenko, Olesya A., Stotz, Stephanie C., Rakai, Brooke D., Sarsons, Christopher D., Gilham, Dean, Wasiak, Sylwia, Fu, Li, Sweeney, Michael, Johansson, Jan O., Wong, Norman C.W., Kulikowski, Ewelina

“…Bromodomain and extraterminal proteins (BETs) are more than just epigenetic regulators of transcription. Here we highlight a new role for the BET protein BRD4…”
Get full text

Apabetalone, a Clinical-Stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells by Sarsons, Christopher D, Gilham, Dean, Tsujikawa, Laura M, Wasiak, Sylwia, Fu, Li, Rakai, Brooke D, Stotz, Stephanie C, Carestia, Agostina, Sweeney, Michael, Kulikowski, Ewelina

“…Facioscapulohumeral dystrophy (FSHD) is a muscle disease caused by inappropriate expression of the double homeobox 4 (DUX4) gene in skeletal muscle, and its…”
Get full text

Apabetalone Downregulates Fibrotic, Inflammatory and Calcific Processes in Renal Mesangial Cells and Patients with Renal Impairment by Gilham, Dean, Wasiak, Sylwia, Rakai, Brooke D, Fu, Li, Tsujikawa, Laura M, Sarsons, Christopher D, Carestia, Agostina, Lebioda, Kenneth, Johansson, Jan O, Sweeney, Michael, Kalantar-Zadeh, Kamyar, Kulikowski, Ewelina

“…Epigenetic mechanisms are implicated in transcriptional programs driving chronic kidney disease (CKD). Apabetalone is an orally available inhibitor of…”
Get full text

The BET inhibitor apabetalone decreases neuroendothelial proinflammatory activation in vitro and in a mouse model of systemic inflammation by Wasiak, Sylwia, Fu, Li, Daze, Emily, Gilham, Dean, Rakai, Brooke D., Stotz, Stephanie C., Tsujikawa, Laura M., Sarsons, Chris D., Studer, Deborah, Rinker, Kristina D., Jahagirdar, Ravi, Wong, Norman C. W., Sweeney, Michael, Johansson, Jan O., Kulikowski, Ewelina

“…Brain vascular inflammation is characterized by endothelial activation and immune cell recruitment to the blood vessel wall, potentially causing a breach in…”
Get full text

Epigenetic Modulation by Apabetalone Counters Cytokine-Driven Acute Phase Response In Vitro, in Mice and in Patients with Cardiovascular Disease by Sweeney, Michael, Johansson, Jan O., Wong, Norman C. W., Kulikowski, Ewelina, Fu, Li, Rakai, Brooke D., Stotz, Stephanie C., Halliday, Christopher, Tsujikawa, Laura M., Daze, Emily, Gilham, Dean, Wasiak, Sylwia, Jahagirdar, Ravi

“…Chronic systemic inflammation contributes to cardiovascular disease (CVD) and correlates with the abundance of acute phase response (APR) proteins in the liver…”
Get full text

Benefit of Apabetalone on Plasma Proteins in Renal Disease by Wasiak, Sylwia, Tsujikawa, Laura M., Halliday, Christopher, Stotz, Stephanie C., Gilham, Dean, Jahagirdar, Ravi, Kalantar-Zadeh, Kamyar, Robson, Richard, Sweeney, Michael, Johansson, Jan O., Wong, Norman C., Kulikowski, Ewelina

“…Apabetalone, a small molecule inhibitor, targets epigenetic readers termed BET proteins that contribute to gene dysregulation in human disorders. Apabetalone…”
Get full text

Inhibition of epigenetic reader proteins by apabetalone counters inflammation in activated innate immune cells from Fabry disease patients receiving enzyme replacement therapy by Fu, Li, Wasiak, Sylwia, Tsujikawa, Laura M., Rakai, Brooke D., Stotz, Stephanie C., Wong, Norman C. W., Johansson, Jan O., Sweeney, Michael, Mohan, Connie M., Khan, Aneal, Kulikowski, Ewelina

“…Fabry disease (FD) is a rare X‐linked disorder of lipid metabolism, characterized by the accumulation of globotriaosylceramide (Gb3) due to defective the…”
Get full text

Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes by Wasiak, Sylwia, Gilham, Dean, Tsujikawa, Laura M., Halliday, Christopher, Norek, Karen, Patel, Reena G., McLure, Kevin G., Young, Peter R., Gordon, Allan, Kulikowski, Ewelina, Johansson, Jan, Sweeney, Michael, Wong, Norman C.

“…Apabetalone (RVX-208) inhibits the interaction between epigenetic regulators known as bromodomain and extraterminal (BET) proteins and acetyl-lysine marks on…”
Get full text

RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease by Gilham, Dean, Wasiak, Sylwia, Tsujikawa, Laura M, Halliday, Christopher, Norek, Karen, Patel, Reena G, Kulikowski, Ewelina, Johansson, Jan, Sweeney, Michael, Wong, Norman C.W

“…Abstract High density lipoproteins (HDL), through activity of the main protein component apolipoprotein A-I (ApoA-I), can reduce the risk of cardiovascular…”
Get full text

Apabetalone downregulates factors and pathways associated with vascular calcification by Gilham, Dean, Tsujikawa, Laura M., Sarsons, Christopher D., Halliday, Christopher, Wasiak, Sylwia, Stotz, Stephanie C., Jahagirdar, Ravi, Sweeney, Michael, Johansson, Jan O., Wong, Norman C.W., Kalantar-Zadeh, Kamyar, Kulikowski, Ewelina

“…Apabetalone is an inhibitor of bromodomain and extraterminal (BET) proteins. In clinical trials, apabetalone reduced the incidence of major adverse cardiac…”
Get full text

Epigenetic BET reader inhibitor apabetalone (RVX-208) counters proinflammatory aortic gene expression in a diet induced obesity mouse model and in human endothelial cells by Wasiak, Sylwia, Tsujikawa, Laura M., Daze, Emily, Gilham, Dean, Stotz, Stephanie C., Rakai, Brooke D., Sarsons, Chris D., Fu, Li, Azhar, Salman, Jahagirdar, Ravi, Sweeney, Michael, Johansson, Jan O., Wong, Norman C.W., Kulikowski, Ewelina

“…Obese patients are at risk for type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). A lipid-rich diet promotes arterial changes by inducing…”
Get full text

Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism by Tsujikawa, Laura M, Fu, Li, Das, Shovon, Halliday, Christopher, Rakai, Brooke D, Stotz, Stephanie C, Sarsons, Christopher D, Gilham, Dean, Daze, Emily, Wasiak, Sylwia, Studer, Deborah, Rinker, Kristina D, Sweeney, Michael, Johansson, Jan O, Wong, Norman C W, Kulikowski, Ewelina

“…Apabetalone (RVX-208) is a bromodomain and extraterminal protein inhibitor (BETi) that in phase II trials reduced the relative risk (RR) of major adverse…”
Get full text

Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation by Fu, Li, Gilham, Dean, Stotz, Stephanie C., Sarsons, Christopher D., Rakai, Brooke D., Tsujikawa, Laura M., Wasiak, Sylwia, Johansson, Jan O., Sweeney, Michael, Wong, Norman C.W., Kulikowski, Ewelina

“…•Epigenetic inhibitor apabetalone reduces SARS-CoV-2 spike protein binding to ACE2 abundant human lung cells regardless of mutations in Delta and Omicron…”
Get full text

Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208) by Wasiak, Sylwia, Gilham, Dean, Tsujikawa, Laura M., Halliday, Christopher, Calosing, Cyrus, Jahagirdar, Ravi, Johansson, Jan, Sweeney, Michael, Wong, Norman C., Kulikowski, Ewelina

“…Apabetalone (RVX-208) is an epigenetic regulator developed to treat cardiovascular disease (CVD) that targets BET proteins. Through transcriptional regulation…”
Get full text

Corrigendum to “RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease” [Atherosclerosis 247 (2016) 48–57] by Gilham, Dean, Wasiak, Sylwia, Tsujikawa, Laura M, Halliday, Christopher, Norek, Karen, Patel, Reena G, Kulikowski, Ewelina, Johansson, Jan, Sweeney, Michael, Wong, Norman C.W

Get full text

Abstract 10591: Epigenetic BET Reader Inhibitor Apabetalone (RVX-208) Counters Proinflammatory Aortic Gene Expression in a Diet Induced Obesity Mouse Model by Wasiak, Sylwia, Daze, Emily, Tsujikawa, Laura M, Gilham, Dean, Sarsons, Christopher, Stotz, Stephanie, Rakai, Brooke, Azhar, Salman, Jahagirdar, Ravi, Sweeney, Michael, Johansson, Jan, Wong, Norman, Kulikowski, Ewelina

“…IntroductionObesity increases the risk of type 2 diabetes (DM2) and cardiovascular disease (CVD), due to associated insulin resistance, dyslipidemia, high…”
Get full text

Abstract 14112: Apabetalone (RVX-208) Reduces ACE2 Expression in Human Cell Culture Systems, Which Could Attenuate SARS-CoV-2 Viral Entry by Gilham, Dean, Fu, Li, Tsujikawa, Laura M, Rakai, Brooke, Wasiak, Sylwia, Stotz, Stephanie, Sarsons, Christopher, Sweeney, Michael, JOHANSSON, Jan, Wong, Norman, Kulikowski, Ewelina

“…IntroductionApabetalone is an orally available small molecule that affects gene transcription by inhibiting BET protein interactions with acetylated histones…”
Get full text

EPIGENETIC READER INHIBITOR APABETALONE (RVX-208) COUNTERS PROINFLAMMATORY HYPERACTIVATION OF CD14+ MONOCYTES FROM PATIENTS WITH TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE by Wasiak, Sylwia, Dzobo, Kim E., Bahjat, Mahnoush, Rakai, Brooke D., Kaiser, Yannick, Versloot, Miranda, Kroon, Jeffrey, Stotz, Stephanie C., Tsujikawa, Laura M., Fu, Li, Gilham, Dean, Sarsons, Christopher D., Sweeney, Michael, Johansson, Jan O., Wong, Norman C.W., Stroes, Erik S.G., Kulikowski, Ewelina

Get full text

BET inhibitor apabetalone (RVX-208) downregulates the complement cascade in primary human hepatocytes, in mice and in cardiovascular disease human patients by Wasiak, Sylwia, Gilham, Dean, Tsujikawa, Laura M., Halliday, Christopher, Calosing, Cyrus, Jahagirdar, Ravi, Johansson, Jan, Sweeney, Michael, Wong, Norman C., Kulikowski, Ewelina

Get full text